Custirsen Does Not Improve Overall Survival in mCRPC

The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer in a phase III trial.

Source: CancerNetwork - March 31, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news